GeoVax Labs Revenue Doubles in Q2
GeoVax Labs (NASDAQ:GOVX), a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer, reported its second quarter 2025 results on July 28, 2025. The company posted GAAP revenue ahead of expectations, and continued to advance its lead clinical programs but highlighted increased operating costs and tightening cash reserves. GAAP revenue rose to $0.85 million, well above the analyst estimate of $0.39 million, while GAAP earnings per share came in at a loss of $(0.35), exceeding expectations of $(0.34). Compared to a $(1.99) GAAP loss per share in Q2 2024, this marks considerable year-over-year improvement. Overall, the period reflected continued scientific progress but also raised red flags regarding future funding and ongoing operating losses.
Source: Analyst estimates for the quarter provided by FactSet.
GeoVax Labs (NASDAQ:GOVX) specializes in the research and development of vaccines and immunotherapies targeting significant unmet needs in infectious diseases, such as COVID-19 and mpox (formerly known as monkeypox), as well as treatment for solid tumors in oncology. Its clinical-stage pipeline is built around three main product families: GEO-CM04S1, a multi-antigen COVID-19 vaccine; GEO-MVA, a vaccine for mpox and smallpox; and Gedeptin, a gene-directed immunotherapy for advanced cancers.
Source Fool.com
